Shaker Mousa
Shaker A. Mousa, PhD is an endowed chair, tenured professor of Pharmacology at Albany College of Pharmacy; Vice Provost of Research, executive vice president, and chair of Pharmaceutical Research Institute at Albany, NY; president of Vascular Vision Pharmaceuticals; and founder of several spin-off pharmaceutical and biotechnology companies. He was a senior principal research scientist and a research fellow at DuPont Pharmaceuticals and Imaging Co., DuPont Merck, and DuPont Pharmaceuticals Company for two decades. He is a recipient of several national and international awards, including the 2017 Kuwait Foundation for Advancement in Sciences (KFAS) Prize for Applied Sciences in Medicine. His work is reported in over 1,000 peer-reviewed publications (Google Scholar h-index = 75, citations = 20,975) and he holds over 400 US and international patents. He contributed to the discovery and development of the following products/clinical candidates: Cardiolite® (Tc99m sestamibi RP30, non-invasive myocardial perfusion imaging agent, Marluma (for breast cancer detection), DMP444 (Tc99m platelet GPIIb/IIIa antagonist for non-invasive thrombus imaging agent in venous and arterial thromboembolic disorders), Breviblock (ultra-short acting beta adrenergic receptor blocker, Esmolol), and Roxifiban (DMP754, oral anti-platelet/Anti-thrombotic agent for the prevention and treatment of coronary, carotid and peripheral artery thromboembolic disorders). His main current research interest is in drug discovery and drug development and bringing novel concepts from the bench to the bedside and vice versa utilizing key enabling technologies, including nanotechnology, biotechnology, stem cell, and pharmacotherapy.